A clinical program presented at ECO2026 and published in Nature Medicine reported that sustained weight loss appears achievable by moving patients from injectable obesity drugs to daily oral orforglipron (ATTAIN-MAINTAIN). Investigators reported results focused on maintenance after induction and aimed to address durability as a core decision point in long-term obesity management. The study adds to a growing evidence base for oral agents that could reduce injection burden while preserving clinical benefit. It also supports a broader industry shift toward maintenance-centric trial endpoints. For developers, the data strengthen the case for designing registration and lifecycle strategies around switching regimens and real-world continuation patterns, which can influence both clinical outcomes and payer coverage dynamics.